Botanicals used in complementary and alternative medicine treatment of cancer: Clinical science and future perspectives

Expert Opinion on Investigational Drugs

Volumn 17, Issue 9, 2008, Pages 1353-1364

  Miller, Scott ^a   Stagl, Jamie ^a   Wallerstedt, Dawn B ^a   Ryan, Mary ^b   Mansky, Patrick J ^a  

^a National Institutes of Health Library ^*  (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Botanical; Cancer symptoms; Cancer treatment; Clinical trials; Complementary and alternative medicine

Indexed keywords

AIFUKANG; ALOE VERA EXTRACT; ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BIO 112; BZL 101; CEPHALOTAXUS HARRINGTONIA EXTRACT; CHINESE DRUG; CUMIN EXTRACT; CURCUMA LONGA EXTRACT; CURCUMIN; GINGER EXTRACT; GRIFOLA FRONDOSA EXTRACT; HOMOHARRINGTONINE; INDIRUBIN; KRESTIN; PAPAVER SOMNIFERUM EXTRACT; PLACEBO; PLANT EXTRACT; QING DAI; RUBIA CORDIFOLIA EXTRACT; SCUTELLARIA BARBATA EXTRACT; SCUTELLARIA RIVULARIS; TRIPTERYGIUM WILFORDII EXTRACT; TRIPTOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VISCUM ALBUM EXTRACT; WITHANIA SOMNIFERA EXTRACT;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AFRICAN MEDICINE; ALOE VERA; ALTERNATIVE MEDICINE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AYURVEDA; BONE MARROW TOXICITY; CANCER PAIN; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CEPHALOTAXUS; CEPHALOTAXUS HARRINGTONIA; CHINESE MEDICINE; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CUMIN; CURCUMA LONGA; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG URINE LEVEL; DRUG USE; EMBASE; EVIDENCE BASED MEDICINE; FATIGUE; GINGER; GRIFOLA; GRIFOLA FRONDOSA; HERBAL MEDICINE; HOMEOPATHY; HUMAN; IN VITRO STUDY; INFORMATION RETRIEVAL; INSOMNIA; MAXIMUM TOLERATED DOSE; MEDICAL LITERATURE; MEDLINE; MENOPAUSAL SYNDROME; MONOTHERAPY; MUCOSA INFLAMMATION; MUSHROOM; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PAPAVER SOMNIFERUM; PHARMACOGNOSY; PHYTOTHERAPY; PLANT ROOT; REVIEW; RUBIA; RUBIA CORDIFOLIA; SCUTELLARIA; SCUTELLARIA BARBATA; SIGNAL TRANSDUCTION; TRAMETES VERSICOLOR; TRIPTERYGIUM; UNSPECIFIED SIDE EFFECT; VISCUM ALBUM; WITHANIA SOMNIFERA;

AGARICALES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG TOXICITY; HUMANS; NEOPLASMS; PHYTOTHERAPY; SANTALACEAE;

EID: 52949112686     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.9.1353     Document Type: Review

References (98)

1. Goldstein MS, Lee JH, Ballard-Barbash R, Brown ER. The use and perceived benefit of complementary and alternative medicine among Californians with cancer. Psychooncology 2008;17(1):19-25
2. Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther 2007;6(2):158-65
3. The Pharmaprojects Database. Informa UK Ltd. 2008. Available from: www.pharmaprojects.com
4. Hughes D, Ladas E, Rooney D, Kelly K. Massage therapy as a supportive care intervention for children with cancer. Oncol Nurs Forum 2008;35(3):431-42
5. Khan S, Balick MJ. Therapeutic plants of ayurveda: a review of selected clinical and other studies for 166 species. J Altern Complement Med 2001;7(5):405-515
6. Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007;31(4):243-305
7. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23(1A):363-98
8. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999;39(1):41-7
9. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993;14(11):2219-25
10. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18(44):6013-20
11. Mukhopadhyay A, Banerjee S, Stafford LJ, et al. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002;21(57):8852-61
12. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesisn 1995;16(8):1741-5
13. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1994;1224(3):597-600
14. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101(3):1053-62
15. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103(8):3175-84
16. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004;172(10):5940-7
17. Singh AK, Sidhu GS, Deepa T, Maheshwari RK. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 1996;107(1):109-15
18. Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ 1998;9(4):305-12
19. Dorai T, Cao YC, Dorai B, et al. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001;47(4):293-303
20. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21(4B):2895-900
21. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10(20):6847-54
22. Dhillon N, Wolff RA, Abbruzzese JL, et al. Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14(14):4491-9
23. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007;595:453-70
24. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75(4):787-809
25. Yodkeeree S, Chaiwangyen W, Garbisa S, et al demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J Nutr Biochem May 19 2008; [Epub ahead of print]
26. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007;28(8):1765-73
27. Dhuley JN. Therapeutic efficacy of Ashwagandha against experimental aspergillosis in mice. Immunopharmacol Immunotoxicol 1998;20(1):191-8
28. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 1998;60(2):173-8
29. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 2003;30(5-6):399-404
30. Kaur K, Rani G, Widodo N, et al. Evaluation of the anti-proliferative and anti-oxidative activities of leaf extract from in vivo and in vitro raised Ashwagandha. Food Chem Toxicol 2004;42(12):2015-20
31. Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern Med Rev 2006;11(4):269-77
32. Christina AJ, Joseph DG, Packialakshmi M, et al. Anticarcinogenic activity of Withania somnifera Dunal against Dalton's ascitic lymphoma. J Ethnopharmacol 2004;93(2-3):359-61
33. Mathur R, Gupta SK, Singh N, et al. Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol 2006;105(3):336-41
34. Mohan R, Hammers HJ, Bargagna-Mohan P, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004;7(2):115-22
35. Ichikawa H, Takada Y, Shishodia S, et al. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther 2006;5(6):1434-45
36. Davis L, Kuttan G. Immunomodulatory activity of Withania somnifera. J Ethnopharmacol 2000;71(1-2):193-200
37. Dhuley JN. Effect of some Indian herbs on macrophage functions in ochratoxin A treated mice. J Ethnopharmacol 1997;58(1):15-20
38. Davis L, Kuttan G. Effect of Withania somnifera on cell mediated immune responses in mice. J Exp Clin Cancer Res 2002;21(4):585-90
39. Rastogi S, Kulshreshtha DK, Rawat AKS. Streblus asper Lour. (Shakhotaka): a review of its chemical, pharmacological and ethnomedicinal properties. Evid Based Complement Altern Med 2006;3(2):217-22
40. Balachandran P, Govindarajan R. Cancer - an ayurvedic perspective. Pharmacol Res 2005;51(1):19-30
41. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002;43(9):1763-8
42. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004;130(11):627-35
43. Knockaert M, Blondel M, Bach S, et al. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 2004;23(25):4400-12
44. Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 2006;25(47):6304-18
45. Rugo H, Shtivelman E, Perez A, et al. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat 2007;105(1):17-28
46. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281(14):9616-22
47. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13(8):353-61
48. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94(7):2024-32
49. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93(12):4149-53
50. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86(9):3322-6
51. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109(2):248-55
52. Jianzhe Y MX. Icons of medicinal fungi from China: Crc Pr I Llc 1987
53. Smith JER, Neil J, Sullivan, R. Medicinal mushrooms: their therapeutic properties and current medical usage with special emphasis on cancer treatments. Strathclyde: University of Strathclyde; 2002
54. Mizutani Y NY, Yoshida O. Effect of PSK and its subfractions on peripheral blood lymphocytes mediated cytotoxicity against urinary bladder tumor cells. J Urol 1992;148(5):1571-6
55. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31(5):261-8
56. Mitomi T TS, Iijima N, Aso K, et al. Randomized, controlled study on adjuvant immunotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992;35:123-30
57. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004 2004;90(5):1003-10
58. Ito K, Nakazato H, Koike A, Takagi H, et al. Study Group of Immunochemotherapy with PSK for Colon Cancer. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7 year follow-up. Int J Colorectal Dis 2004;19(2):157-64
59. Oba K, Teramukai S, Kobayashi M, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 2007;56(6):905-11
60. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 1998;30(1):1-4
61. NCI Dictionary of Cancer Terms. Biological response modifier therapy 2007 [cited]. Available from: http://www.cancer.gov/Templates/ db_alpha.aspx?CdrID=45616
62. Chang R. Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. J Altern Complement Med 2002;8(5):559-65
63. Sullivan R, Smith JE, Rowan NJ. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 2006;49(2):159-70
64. Mao T. Two mushrooms, Grifola frondosa and Ganoderma lucidum, can stimulate cytokine gene expression and proliferation in human T lymphocytes. Int J Immunother 1999;15:13-22
65. Shiao M. Natural products and biological activities of Ganoderma lucidum. Am Chem Soc 1994;342-54
66. Steiner R. Geisteswissenschaft und Medizin. 6th edition. Dornach: Rudolf Steiner Verlag; 1985
67. Kelly KM. Bringing evidence to complementary and alternative medicine in children with cancer: focus on nutrition-related therapies. Pediatr Blood Cancer 2008;50(2 Suppl):490-3; discussion 8
68. Kienle GS, Kiene H. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003
69. Semiglazov VF, Stepula VV, Dudov A, et al. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006;26(2B):1519-29
70. Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24(1):303-9
71. Horneber MA, Bueschel G, Huber R, et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008;2: CD003297
72. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000;84(3):367-71
73. Kienle GS, Berrino F, Bussing A, et al. Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 2003;8(3):109-19
74. Mansky PJ. Mistletoe and cancer: controversies and perspectives. Semin Oncol 2002;29(6):589-94
75. Mabed M, El-Helw L, Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004;90(1):65-9
76. Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18(13):2505-14
77. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000;84(3):367-71
78. Sontakke S, Thawani V, Naik MS. Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Indian J Pharmacol 2003;35(1):32-6
79. Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. Cancer J 2006;12(5):425-31
80. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev 2005;1:CD004540
81. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev 2007;2:CD004921
82. Xu L, Lao LX, Ge A, et al. Chinese herbal medicine for cancer pain. Integr Cancer Ther 2007;6(3):208-34
83. Elam JL, Carpenter JS, Shu XO, et al. Methodological issues in the investigation of ginseng as an intervention for fatigue. Clin Nurse Spec 2006;20(4):183-9
84. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther 2004;3(2):128-48
85. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7(8):2182-94
86. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006;11(7):742-52
87. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355(9203):547-8
88. Su CK, Mehta V, Ravikumar L, et al. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys 2004;60(1):171-7
89. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007;4:CD000978
90. Oberbaum M, Yaniv I, Ben-Gal Y, et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer 2001;92(3):684-90
91. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;24(18):2836-41
92. Walji R, Boon H, Guns E, et al. Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Support Care Cancer 2007;15(8):913-21
93. Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancer-related symptoms. J Support Oncol 2004;2(5):419-26; discussion 27-9
94. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 2007;57(5):260-77
95. Touillaud MS, Thiebaut AC, Fournier A, et al. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007;99(6):475-86
96. Van Schalkwyk J, Davidson J, Palmer B, Hope V. Ayurvedic medicine: patients in peril from plumbism. N Z Med J 2006;119(1233):U1958
97. Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004;292(23):2868-73
98. Buchanan DR, White JD, O'Mara AM, et al. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program Experience. J Clin Oncol 2005;23(27):6682-9